Claus Holst‐Hansen

2.2k total citations · 1 hit paper
26 papers, 1.8k citations indexed

About

Claus Holst‐Hansen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Claus Holst‐Hansen has authored 26 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Claus Holst‐Hansen's work include Protease and Inhibitor Mechanisms (8 papers), Phonocardiography and Auscultation Techniques (7 papers) and Music and Audio Processing (4 papers). Claus Holst‐Hansen is often cited by papers focused on Protease and Inhibitor Mechanisms (8 papers), Phonocardiography and Auscultation Techniques (7 papers) and Music and Audio Processing (4 papers). Claus Holst‐Hansen collaborates with scholars based in Denmark, United States and Belgium. Claus Holst‐Hansen's co-authors include Nils Brünner, Samuel Emil Schmidt, Johannes J. Struijk, Egon Toft, Claus Graff, Peter Carmeliet, Véronique Masson, Norbert E. Fusenig, Robert D. Gerard and Khalid Bajou and has published in prestigious journals such as Nature Medicine, Biochemistry and British Journal of Cancer.

In The Last Decade

Claus Holst‐Hansen

26 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

1998 574 citations Khalid Bajou, Agnès Noël et al. Nature Medicine profile →

Peers

Countries citing papers authored by Claus Holst‐Hansen

Since Specialization

Citations

This map shows the geographic impact of Claus Holst‐Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Holst‐Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Holst‐Hansen more than expected).

Fields of papers citing papers by Claus Holst‐Hansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claus Holst‐Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Holst‐Hansen. The network helps show where Claus Holst‐Hansen may publish in the future.

Co-authorship network of co-authors of Claus Holst‐Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Claus Holst‐Hansen. A scholar is included among the top collaborators of Claus Holst‐Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claus Holst‐Hansen. Claus Holst‐Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acoustic Features for the Identification of Coronary Artery Disease 2015 ·IEEE Transactions on Biomedical Engineering ·Samuel Emil Schmidt, Claus Holst‐Hansen, John Hansen, Egon Toft, Johannes J. Struijk	90
2	Partial oral treatment of endocarditis 2013 ·American Heart Journal ·Kasper Iversen, Nis Høst, Niels Eske Bruun, Hanne Elming, Bettina Pump, Jens Jørgen Christensen, Sabine Gill, Flemming Schønning Rosenvinge, Henrik Wiggers, Kurt Fuursted, Claus Holst‐Hansen, Eva Korup, Henrik Carl Schønheyder, Christian Hassager, Dan Eik Høfsten, Jannik Helweg‐Larsen, Claus Moser, Nikolaj Ihlemann, Henning Bundgaard	27
3	Comparison of Human Adipose-Derived Stem cells and Bone Marrow-Derived Stem cells in a Myocardial Infarction Model 2013 ·Cell Transplantation ·Jeppe Grøndahl Rasmussen, Ole Fröbert, Claus Holst‐Hansen, Jens Kastrup, Ulrik Baandrup, Vladimir Zachar, Trine Fink, Ulf Simonsen	69
4	Segmentation of heart sound recordings by a duration-dependent hidden Markov model 2010 ·Physiological Measurement ·Samuel Emil Schmidt, Claus Holst‐Hansen, Claus Graff, Egon Toft, Johannes J. Struijk	220
5	Noise and the detection of coronary artery disease with an electronic stethoscope 2010 ·VBN Forskningsportal (Aalborg Universitet) ·Samuel Emil Schmidt, Egon Toft, Claus Holst‐Hansen, Johannes J. Struijk	17
6	Can new pulmonary gas exchange parameters contribute to evaluation of pulmonary congestion in left-sided heart failure? 2009 ·Canadian Journal of Cardiology ·(unknown), Jens Kristensen, Jerzy Malczynski, Claus Holst‐Hansen, Stephen Edward Rees, (unknown), Steen Andreassen, Jens Brøndum Frøkjær, Egon Toft	3
7	Segmentation of heart sound recordings by a duration dependent Hidden Markov Model 2009 ·VBN Forskningsportal (Aalborg Universitet) ·Samuel Emil Schmidt, Egon Toft, Claus Holst‐Hansen, Claus Graff, Johannes J. Struijk	15
8	Detection of coronary artery disease with an electronic stethoscope: is it possible? 2007 ·VBN Forskningsportal (Aalborg Universitet) ·Samuel Emil Schmidt, Claus Holst‐Hansen, Egon Toft, Johannes J. Struijk	2
9	Measurement of tumor load and distribution in a model of cancer-induced osteolysis: A necessary precaution when testing novel anti-resorptive therapies 2004 ·Clinical & Experimental Metastasis ·(unknown), Pernille Høegh-Andersen, Nils Brünner, Annette Sørensen, Bent Winding, Claus Holst‐Hansen, M.A. Karsdal, Michael T. Engsig, Jean‐Marie Delaissé, Anne‐Marie Heegaard	4
10	Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat 2001 ·Breast Cancer Research and Treatment ·Claus Holst‐Hansen, Jennifer A. Low, Ross W. Stephens, Michael D. Johnson, Peter Carmeliet, Thomas Leth Frandsen, Nils Brünner, Robert B. Dickson	7
11	Peptide-Derived Antagonists of the Urokinase Receptor. Affinity Maturation by Combinatorial Chemistry, Identification of Functional Epitopes, and Inhibitory Effect on Cancer Cell Intravasation 2001 ·Biochemistry ·Michael Ploug, Søren Østergaard, Henrik Gårdsvoll, (unknown), Claus Holst‐Hansen, Arne Holm, Liliana Ossowski, Keld Danø	156
12	Plasma Escherichia Coli β-Galactosidase as a Marker of Tumor Burden and Response to Experimental Anti-Neoplastic Therapy in Nude Mice Xenografted with lacZ Transduced Human Tumor Cells 2000 ·Laboratory Investigation ·Claus Holst‐Hansen, Ross W. Stephens, (unknown), Peter Buhl Jensen, Nils Brünner	3
13	Soluble urokinase receptor released from human carcinoma cells: A plasma parameter for xenograft tumour studies 1999 ·British Journal of Cancer ·Claus Holst‐Hansen, Maria J. A. G. Hamers, (unknown), Nils Brünner, Ross W. Stephens	30
14	Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization breakdown → 1998 ·Nature Medicine ·Khalid Bajou, Agnès Noël, Robert D. Gerard, Véronique Masson, Nils Brünner, Claus Holst‐Hansen, Mihaela Skobe, Norbert E. Fusenig, Peter Carmeliet, D Collen, J.M. Foidart	574
15	A new immunocapture assay for Escherichia coli beta-galactosidase for in vivo studies of lacZ-transduced tumor cells. 1998 ·PubMed ·Claus Holst‐Hansen, N. Brünner, (unknown), (unknown), Ross W. Stephens	4
16	Effect of NCAM‐transfection on growth and invasion of a human cancer cell line 1997 ·Apmis ·Klaus Edvardsen, Elisabeth Bock, (unknown), Thomas Leth Frandsen, Claus Holst‐Hansen, Claus Moser, Mogens Spang‐Thomsen, Nina Marie Pedersen, Frank S. Walsh, Lars L. Vindeløv, Nils Brünner	12
17	MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. 1997 ·PubMed ·Nils Brünner, (unknown), (unknown), Todd C. Skaar, Claus Holst‐Hansen, (unknown), Thomas Leth Frandsen, Mogens Spang‐Thomsen, Suzanne A.W. Fuqua, Robert Clarke	160
18	Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness 1996 ·Clinical & Experimental Metastasis ·Claus Holst‐Hansen, (unknown), Gunilla Høyer‐Hansen, John Rømer, Vincent Ellis, Nils Brünner	111
19	Acquisition of estrogen independence and antiestrogen resistance in breast cancer: association with the invasive and metastatic phenotype 1995 ·Endocrine Related Cancer ·Nils Brünner, Michael D. Johnson, Claus Holst‐Hansen, Jens Folke Kiilgaard, Erik W. Thompson, Robert Clarke	2
20	MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. 1993 ·PubMed ·Nils Brünner, Thomas Leth Frandsen, Claus Holst‐Hansen, (unknown), Erik W. Thompson, Alan E. Wakeling, Marc E. Lippman, Robert Clarke	94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact